Episcleritis

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Retrieved on: 
четверг, мая 9, 2024
Adverum Biotechnologies, FDA, AMD, Patient, Inflammation, Retinitis, Investment, Safety, CST, Research, Chorioretinitis, Compensated emancipation, Vascular occlusion, Employment, Macula, Episcleritis, Data, OPTIC, Three Months, Vasculitis, Society, LUNA, Intraocular pressure, VEGF, ASRS, Injection, Pharmaceutical industry

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the first quarter of 2024. The company also provided recent pipeline highlights.

Key Points: 
  • “Our presentation will feature a 26-week landmark interim analysis, which is expected to serve as the basis of our FDA end-of-Phase 2 meeting.
  • The award was granted under the Adverum Biotechnologies, Inc. 2017 Inducement Plan, as amended and restated, and will vest over four years, subject to continued service with Adverum.
  • Stock-based compensation expense included in research and development expenses was $1.1 million for the first quarter of 2024.
  • Stock-based compensation expense included in general and administrative expenses was $3.0 million for the first quarter of 2024.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Retrieved on: 
понедельник, марта 18, 2024
Research, Adverum Biotechnologies, Vasculitis, Three Months, Macula, Chorioretinitis, Inflammation, Patient, Episcleritis, American Academy, Anti-VEGF, LUNA, Intraocular pressure, Investment, Clinical trial, Injection, Safety, Drug development, Paratriathlon, AMD, AAO, OPTIC, Retinitis, CST, Vascular occlusion, Annual general meeting, VEGF, Pharmaceutical industry

REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.

Key Points: 
  • The company also provided recent pipeline highlights and corporate updates.
  • 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
  • Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.

Relapsing Polychondritis Foundation Announces Appointment of Frances Sweeney to Board of Directors

Retrieved on: 
понедельник, января 9, 2023
RP, Child, Federal Reserve Bank of New York, Citibank, MBA, Boston University, Patient, Encore Capital Group, Economics, Degenerative disease, Episcleritis, Federal Reserve Bank, Computer science, Race, Capital Group Companies, Management, New York University

NEW YORK, Jan. 9, 2023 /PRNewswire-PRWeb/ -- The Relapsing Polychondritis Foundation (RP Foundation) is pleased to announce the appointment of Frances "Fran" Sweeney to its Board of Directors effective December 11, 2022.

Key Points: 
  • This information is from the Relapsing Polychondritis Foundation Inc. with Race for RP.
  • NEW YORK, Jan. 9, 2023 /PRNewswire-PRWeb/ -- The Relapsing Polychondritis Foundation (RP Foundation) is pleased to announce the appointment of Frances "Fran" Sweeney to its Board of Directors effective December 11, 2022.
  • "We are honored to welcome Fran Sweeney to the RP Foundation Board," said David Bammert, President and Director.
  • For more information about relapsing polychondritis, the RP Foundation, and the Race for RP, please visit https://polychondritis.org and https://raceforrp.org .

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

Retrieved on: 
вторник, октября 4, 2022
Association, Injection, Neutralizing antibody, CLS, AES, SCS, Eye, Sequela, Therapy, Axitinib, CRT, Visual acuity, NASDAQ, Uveitis, Neoplasm, Intraocular pressure, American Academy, Triamcinolone, Severe cognitive impairment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clearside, Macular edema, Surgeon, Intravitreal injection, AAO, Inflammation, Ranibizumab, Adult, Food, MBA, Highway Rider, Treatment, GLOBE, Incidence, Șaeș, Episcleritis, Retina, Conjunctivitis, Choroid, Safety, NYSE, Pharmaceutical industry, Medical device, Medical imaging, Vaccine, Cohort, Patient

ALPHARETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons.

Key Points: 
  • The interest of the medical community in delivering drugs to the suprachoroidal space is extraordinary.
  • We look forward to additional near-term data being generated and reported across all of these clinical-stage programs, Dr. Ciulla concluded.
  • Cohorts 5 and 6 received up to three cycles of therapy, which was considered the therapeutic regimen for evaluation.
  • Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS).

The Relapsing Polychondritis Foundation Invests in the Next Phase of VEXAS Research

Retrieved on: 
четверг, марта 31, 2022
Disease, Giant cell arteritis, Race, Trachea, Febrile neutrophilic dermatosis, NYU Langone Health, Hematology, Letter, VEXAS syndrome, Classification, Catholic University of Leuven (1834–1968), Internal medicine, Degenerative disease, Genomics, Lists of diseases, Diagnosis, Fever of unknown origin, NEW, Polyarteritis nodosa, Mortality, Cartilage, Inflammation, Nose, Research, Aorta, Episcleritis, RP, Hypoesthesia, Joint, Autoimmune disease, Vacuole, Anemia, UBA1, NIH, Society, Sex linkage, Physician, Science, Genetics, Awareness, Fatigue, Rash, Division, Patient, American Society of Hematology, Pharmaceutical industry, Medical device, Medicine, Animal, VEXAS, Lupus, Rheumatology

NEW YORK, March 31, 2022 /PRNewswire-PRWeb/ --VEXAS is an acronym for: Vacuoles, E1 ubiquitin Activating Enzyme, X-linked, Autoinflammatory, Somatic, with each letter representing one of the hallmark features of this novel autoinflammatory syndrome¹,². The discovery of VEXAS syndrome is revolutionary because it demonstrated that autoimmune disorders previously thought to be unrelated to each other, like relapsing polychondritis (RP), polyarteritis nodosa, Sweet syndrome, and giant cell arteritis, share a common acquired, somatic mutation in the UBA1 gene². UBA1 gene mutations result in the decreased production of an enzyme that breaks-down misfolded proteins and are clinically associated with systemic inflammation, anemia, and bone marrow dysplasia.

Key Points: 
  • To learn more about VEXAS and the research that the RP Foundation's support is expanding upon, check out the following articles:
    1.
  • The Relapsing Polychondritis (RP) Foundation is a 501(c)3, non-profit organization whose mission is to increase awareness and educate the broader community and medical professionals regarding relapsing polychondritis and RP-related autoimmune diseases, and support research initiatives that advance the path to a cure.
  • The Race for RP drives awareness and accelerates research support for the Relapsing Polychondritis Foundation.
  • We're working with the Relapsing Polychondritis Foundation to facilitate research and studies to help diagnose, prevent, and cure RP and its related diseases.

Relapsing Polychondritis Patients, Advocates, and Researchers Emphasize Awareness and Collaboration During Rare Disease Day 2022 at the National Institutes of Health

Retrieved on: 
четверг, марта 17, 2022
Motorsport, Organization, University, Therapy, All In, DRS, Degenerative disease, Michael, Vasculitis, Autoimmunity, Cartilage, Research, Social media, Disease, Episcleritis, RP, National Center for Advancing Translational Sciences, Patient, Poster, Communication, Autoimmune disease, NIH, National, National Institutes of Health Clinical Center, Rare disease, Ferrari Challenge, Awareness, NCATS, Partnership, Pharmaceutical industry, Kerosene, Race, Hope, Rheumatology

NEW YORK, March 17, 2022 /PRNewswire-PRWeb/ --The National Institutes of Health (NIH) Clinical Center held its annual event, Rare Disease Day at the NIH , on February 28, 2022.

Key Points: 
  • NEW YORK, March 17, 2022 /PRNewswire-PRWeb/ --The National Institutes of Health (NIH) Clinical Center held its annual event, Rare Disease Day at the NIH , on February 28, 2022.
  • This year's Rare Disease Day exhibits supported by the Relapsing Polychondritis Foundation included presentations by patients, advocates, and researchers.
  • Written, composed, and performed in support of Race for RP and the RP Foundation, Stefanie's song raised awareness and helped to advance research for the rare autoimmune disease.
  • Race for RP supports research, awareness programs, and care, for those affected by relapsing polychondritis and related diseases.

REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021

Retrieved on: 
пятница, ноября 12, 2021
Society, American Academy of Ophthalmology, Șaeș, Ranibizumab, Consultant, Episcleritis, Securities Exchange Act of 1934, Growth, GC, COVID-19, Diabetic retinopathy, Screening, ASRS, DME, VEGF, Drug Quality and Security Act, Visual acuity, Safety, Financial condition report, DR, Technology, Research, Securities Act of 1933, Injection, Intention, Severe cognitive impairment, PDR, Patient, AAV, CRT, U.S. Securities and Exchange Commission, Conjunctivitis, Eye, Inflammation, Program, Risk, American Academy, SEC, Analysis, Result, Conversation, Retina, Macular degeneration, Neutralizing antibody, AAO, Annual report, AMD, NAV, Perception, Incidence, Death, Pharmaceutical industry, Vaccine, Medical device

AAVIATE is a multi-center, open-label, randomized, active-controlled, dose-escalation trial that will evaluate the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314 using the SCS Microinjector.

Key Points: 
  • AAVIATE is a multi-center, open-label, randomized, active-controlled, dose-escalation trial that will evaluate the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314 using the SCS Microinjector.
  • Cohort 3 is evaluating RGX-314 at the same dose level as Cohort 2 in 20 patients who are neutralizing antibody (NAb) positive.
  • Enrollment is ongoing in two additional cohorts (Cohorts 4 and 5) to evaluate RGX-314 at a third dose level of 1x1012 GC/eye.
  • RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions.